<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00967538</url>
  </required_header>
  <id_info>
    <org_study_id>Inno-6011</org_study_id>
    <secondary_id>CA-2009-0004</secondary_id>
    <nct_id>NCT00967538</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments</brief_title>
  <official_title>Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovaderm Research Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Innovaderm Research Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and efficacy of etanercept in patients with&#xD;
      psoriasis who had an unsatisfactory response to adalimumab and infliximab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who reach a Physician's Global Assessment (PGA) of clear or almost clear after 12 and 24 weeks of etanercept for patients who have shown an unsatisfactory response to adalimumab 40 mg every other week (EOW).</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who reach a PGA of clear or almost clear after 12 and 24 weeks of etanercept for patients who have lost their satisfactory response to adalimumab 40 mg EOW.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who reach a PGA of clear or almost clear after 12 and 24 weeks of etanercept for patients who have lost their satisfactory response to infliximab.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Body Surface Area (BSA) after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to infliximab.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BSA after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to adalimumab 40 mg EOW.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BSA after 12 and 24 weeks of etanercept for patients who have shown an unsatisfactory response to adalimumab 40 mg EOW.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Psoriasis Area and Severity Index (PASI) score after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to infliximab.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PASI score after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to adalimumab 40 mg EOW.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PASI score after 12 and 24 weeks of etanercept for patients who have shown an unsatisfactory response to adalimumab 40 mg EOW.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of etanercept in patients who have shown an unsatisfactory response to adalimumab, who have lost their satisfactory response to adalimumab or who have lost their satisfactory response to infliximab.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept 50 mg</intervention_name>
    <description>All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has plaque psoriasis and has shown an unsatisfactory response to adalimumab.&#xD;
             Unsatisfactory response is defined as patients who failed to reach a PGA of clear or&#xD;
             almost clear (PGA of 0 or 1) following at least 12 weeks with adalimumab at 40 mg EOW;&#xD;
             OR&#xD;
&#xD;
          -  Patient has plaque psoriasis and has lost his/her satisfactory response to adalimumab.&#xD;
             Loss of satisfactory response is defined as patients treated with adalimumab 40 mg EOW&#xD;
             for at least 12 weeks, who achieved a PGA of clear or almost clear (PGA of 0 or 1) but&#xD;
             lost this PGA response (increase in PGA to 2, 3, 4 or 5) at any time after 12 weeks of&#xD;
             adalimumab; OR&#xD;
&#xD;
          -  Patient has plaque psoriasis and has lost his/her satisfactory response to infliximab.&#xD;
             Loss of satisfactory response is defined as patients treated with at least 3&#xD;
             infliximab infusions at 5 mg/kg, who achieved a PGA of clear or almost clear (PGA of 0&#xD;
             or 1) but lost this PGA response (increase in PGA to 2, 3, 4 or 5) at any time after&#xD;
             the 3rd infusion of infliximab;&#xD;
&#xD;
          -  Patient's age is 18 to 80 years old;&#xD;
&#xD;
          -  Patient has PGA of 3 or more at Day 0;&#xD;
&#xD;
          -  Patient has BSA of 3% or more at Day 0;&#xD;
&#xD;
          -  Patient has psoriasis severe enough to be eligible to systemic therapy;&#xD;
&#xD;
          -  Unless surgically sterile (or at least 1 year post-menopausal for women), or&#xD;
             abstinent, patient (male or female) is willing to use an effective method of&#xD;
             contraception for at least 30 days before Day 0 and until at least 1 month after the&#xD;
             last drug administration;&#xD;
&#xD;
          -  Patient capable of giving informed consent;&#xD;
&#xD;
          -  Patient with normal or non clinically significant chest X-ray within 6 months prior to&#xD;
             Day 0;&#xD;
&#xD;
          -  Patient with negative Purified Protein Derivative (PPD) or Quantiferon TB Gold test&#xD;
             within 90 days prior to Day 0;&#xD;
&#xD;
          -  Female patients of childbearing potential have a negative serum pregnancy test;&#xD;
&#xD;
          -  Patient is able to start etanercept per the approved product monograph.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has used topical steroids, topical tar preparations, or other anti-psoriatic&#xD;
             preparations within the two weeks prior to Day 0 or during the study period, unless&#xD;
             patient used topical therapy during the last 4 weeks of the period when the patient&#xD;
             lost their satisfactory response to adalimumab or infliximab or when the patient&#xD;
             failed to achieve a satisfactory response to adalimumab;&#xD;
&#xD;
          -  Patient has presence of erythrodermic, pustular or guttate psoriasis;&#xD;
&#xD;
          -  Patient has had significant infections within the 30 days prior to Day 0;&#xD;
&#xD;
          -  Patient has received investigational drugs within the four weeks prior to screening or&#xD;
             during the study period;&#xD;
&#xD;
          -  Patient has been treated with systemic anti-psoriatic drugs such as steroids,&#xD;
             retinoids, cyclosporine, PUVA therapy or methotrexate within the four weeks prior to&#xD;
             Day 0 or during the study period;&#xD;
&#xD;
          -  Patient received systemic antibiotics within the four weeks prior to Day 0;&#xD;
&#xD;
          -  Patient has been treated with ultraviolet light therapy (UVB, nbUVB) within the two&#xD;
             weeks prior to Day 0 or during the study period;&#xD;
&#xD;
          -  Patient has used adalimumab or infliximab within 14 days of Day 0 or during the study&#xD;
             period;&#xD;
&#xD;
          -  Patient has used other biologic agents for the treatment of psoriasis besides&#xD;
             etanercept 8 weeks prior to Day 0 or during the study period;&#xD;
&#xD;
          -  Patient has had an allergic reaction to adalimumab, infliximab or etanercept;&#xD;
&#xD;
          -  Patient has an unstable or serious medical condition as defined by the investigator or&#xD;
             presence of any significant medical condition that might cause this study to be&#xD;
             detrimental to the patient;&#xD;
&#xD;
          -  Uncontrolled or severe comorbidities such as poorly controlled diabetes mellitus, NYHA&#xD;
             class III or IV heart failure, history of myocardial infarction or cerebrovascular&#xD;
             accident or transient ischemic attack within three months of screening visit; unstable&#xD;
             angina pectoris; uncontrolled hypertension, oxygen-dependent severe pulmonary disease;&#xD;
&#xD;
          -  Patient has a known sero-positivity for HIV virus or history of any other&#xD;
             immunosuppressive disease;&#xD;
&#xD;
          -  Patient has active or chronic Hepatitis B or C;&#xD;
&#xD;
          -  Patient has any mycobacterial disease, patient with a chest X-Ray suggestive of&#xD;
             tuberculosis or patient taking anti-tuberculosis medication;&#xD;
&#xD;
          -  Patient has a known hypersensitivity to etanercept or one of its components;&#xD;
&#xD;
          -  Patient has received a live attenuated vaccine within the 12 weeks prior to Day 0 or&#xD;
             plans to receive one during the study;&#xD;
&#xD;
          -  Current pregnancy or lactation;&#xD;
&#xD;
          -  At the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald B Vender, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatrials Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Bissonnette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innovaderm Research Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kirk Barber Research</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2S3B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PerCuro Clinical Research Ltd</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Clinic Dermatology Research</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research</name>
      <address>
        <city>St John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Lab Clinical Research</name>
      <address>
        <city>St John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Canada Cutaneous Research Associates Ltd</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatrials Research</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mediprobe Research Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M4A 2V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sudbury Skin Clinic</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Jay Brian Taradash</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1R1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena Medical Research</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Esthetique Dr Isabelle Delorme</name>
      <address>
        <city>St-Hyacinthe</city>
        <state>Quebec</state>
        <zip>J2S 6L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherches Dermatologiques du Quebec Metropolitain</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>August 26, 2009</study_first_submitted>
  <study_first_submitted_qc>August 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2009</study_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>etanercept</keyword>
  <keyword>efficacy</keyword>
  <keyword>response</keyword>
  <keyword>anti-TNF alpha</keyword>
  <keyword>treatment efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

